Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
S W M Lammers, M Meegdes, I J H Vriens, A C Voogd, L de Munck, T J A van Nijnatten, K B M I Keymeulen, V C G Tjan-Heijnen, S M E Geurts
BACKGROUND: Several factors may increase the risk of recurrence of patients diagnosed with hormone receptor-positive human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer (BC). We aim to determine the proportion of patients with high-risk HR+/HER2- BC within the total HR+/HER2- BC cohort and compare their systemic treatments and survival rates with those of patients with low- and intermediate-risk HR+/HER2- BC and triple-negative (TN) BC. PATIENTS AND METHODS: Women diagnosed with nonmetastatic invasive HR+/HER2- BC and TNBC in the Netherlands between 2011 and 2019 were identified from the Netherlands Cancer Registry...
April 26, 2024: ESMO Open
#22
JOURNAL ARTICLE
Samuel A Kareff, Asaad Trabolsi, Harris B Krause, Timothy Samec, Andrew Elliott, Estelamari Rodriguez, Coral Olazagasti, Dionysios C Watson, Matias A Bustos, Dave S B Hoon, Stephanie L Graff, Emmanuel S Antonarakis, Sanjay Goel, George Sledge, Gilberto Lopes
Tipifarnib is the only targeted therapy breakthrough for HRAS -mutant ( HRAS mt) recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The molecular profiles of HRAS mt cancers are difficult to explore given the low frequency of HRAS mt. This study aims to understand the molecular co-alterations, immune profiles, and clinical outcomes of 524 HRAS mt solid tumors including urothelial carcinoma (UC), breast cancer (BC), non-small-cell lung cancer (NSCLC), melanoma, and HNSCC. HRAS mt was most common in UC (3...
April 19, 2024: Cancers
#23
JOURNAL ARTICLE
Dominik Dannehl, Alexandra von Au, Tobias Engler, Léa Louise Volmer, Raphael Gutsfeld, Johannes Felix Englisch, Markus Hahn, Sabine Hawighorst-Knapstein, Ariane Chaudhuri, Armin Bauer, Markus Wallwiener, Florin-Andrei Taran, Diethelm Wallwiener, Sara Yvonne Brucker, Stephanie Wallwiener, Andreas Daniel Hartkopf, Tjeerd Maarten Hein Dijkstra
Breast cancer is the leading cause of cancer-related mortality among women in Germany and worldwide. This retrospective claims data analysis utilizing data from AOK Baden-Wuerttemberg, a major statutory German health insurance provider, aimed to construct and assess a real-world data breast cancer disease model. The study included 27,869 female breast cancer patients and 55,738 age-matched controls, analyzing data from 2010 to 2020. Three distinct breast cancer stages were analyzed: Stage A (early breast cancer without lymph node involvement), Stage B (early breast cancer with lymph node involvement), and Stage C (primary distant metastatic breast cancer)...
April 13, 2024: Cancers
#24
REVIEW
Savannah R Brown, Emilie E Vomhof-DeKrey
Breast cancer receives the most funding when compared to any other cancer type, according to a global study conducted by The Lancet . Nevertheless, this malignancy remains the most diagnosed cancer among women and relies heavily on a neoadjuvant treatment regimen of chemotherapy and targeted therapy. After standard treatment, 25-30% of breast cancer patients still develop disease recurrence and must undergo cytoreductive debulking surgery followed by intensive chemotherapy. An array of targeted therapies are currently being utilized and developed to alleviate negative side effects, eradicate cancer growth, and diminish disease recurrence...
April 18, 2024: Biomedicines
#25
JOURNAL ARTICLE
Valentina E Bounous, Carola Minella, Luca Fuso, Silvia Actis, Greta Petroni, Luca G Sgrò, Martina Borghese, Nicoletta Tomasi Cont, Riccardo Ponzone, Annamaria Ferrero
BACKGROUND: pregnancy-associated breast cancer (PABC) affects one in 3000 pregnancies, often presenting with aggressive features. METHODS: We retrospectively evaluated a cohort of 282 young BC patients (≤45 years old) treated between 1995 and 2019, dividing them into three groups: nulliparous women, women with PABC (diagnosed within 2 years since last pregnancy) and women with BC diagnosed > 2 years since last pregnancy. This last group was further stratified according to the time between pregnancy and BC...
April 19, 2024: Current Oncology
#26
JOURNAL ARTICLE
M Bradbury, M F Savard, C Stober, L Clemons, M Clemons, J Hilton, G Pond, L Vandermeer, S F McGee
PURPOSE: Despite previous studies proposing shorter durations of anti-HER2 therapy for selected patients with HER2-positive early breast cancer (EBC), 12-months remains standard of care. A survey was performed to assess patient perspectives and willingness to participate in studies evaluating shorter durations of anti-HER2 therapy. METHODS: Patients with HER2-positive EBC completing or having previously completed anti-HER2 therapy, were recruited by healthcare professionals at The Ottawa Hospital Cancer Centre to participate in an anonymous online survey...
April 25, 2024: Breast Cancer Research and Treatment
#27
JOURNAL ARTICLE
Giacomo Montagna, Mary M Mrdutt, Susie X Sun, Callie Hlavin, Emilia J Diego, Stephanie M Wong, Andrea V Barrio, Astrid Botty van den Bruele, Neslihan Cabioglu, Varadan Sevilimedu, Laura H Rosenberger, E Shelley Hwang, Abigail Ingham, Bärbel Papassotiropoulos, Bich Doan Nguyen-Sträuli, Christian Kurzeder, Danilo Díaz Aybar, Denise Vorburger, Dieter Michael Matlac, Edvin Ostapenko, Fabian Riedel, Florian Fitzal, Francesco Meani, Franziska Fick, Jacqueline Sagasser, Jörg Heil, Hasan Karanlik, Konstantin J Dedes, Laszlo Romics, Maggie Banys-Paluchowski, Mahmut Muslumanoglu, Maria Del Rosario Cueva Perez, Marcelo Chávez Díaz, Martin Heidinger, Mathias K Fehr, Mattea Reinisch, Mustafa Tukenmez, Nadia Maggi, Nicola Rocco, Nina Ditsch, Oreste Davide Gentilini, Regis R Paulinelli, Sebastián Solé Zarhi, Sherko Kuemmel, Simona Bruzas, Simona di Lascio, Tamara K Parissenti, Tanya L Hoskin, Uwe Güth, Valentina Ovalle, Christoph Tausch, Henry M Kuerer, Abigail S Caudle, Jean-Francois Boileau, Judy C Boughey, Thorsten Kühn, Monica Morrow, Walter P Weber
IMPORTANCE: Data on oncological outcomes after omission of axillary lymph node dissection (ALND) in patients with breast cancer that downstages from node positive to negative with neoadjuvant chemotherapy are sparse. Additionally, the best axillary surgical staging technique in this scenario is unknown. OBJECTIVE: To investigate oncological outcomes after sentinel lymph node biopsy (SLNB) with dual-tracer mapping or targeted axillary dissection (TAD), which combines SLNB with localization and retrieval of the clipped lymph node...
April 25, 2024: JAMA Oncology
#28
JOURNAL ARTICLE
Srinivas Veerla, Johan Staaf
Kataegis is a hypermutation phenomenon characterized by localized clusters of single base pair substitution (SBS) reported in multiple cancer types. Despite a high frequency in breast cancer, large-scale analyses of kataegis patterns and associations with clinicopathological and molecular variables in established breast cancer subgroups are lacking. Therefore, WGS profiled primary breast cancers (n = 791) with associated clinical and molecular data layers, like RNA-sequencing data, were analyzed for kataegis frequency, recurrence, and associations with genomic contexts and functional elements, transcriptional patterns, driver alterations, homologous recombination deficiency (HRD), and prognosis in tumor subgroups defined by ER, PR, and HER2/ERBB2 status...
April 24, 2024: NPJ Breast Cancer
#29
REVIEW
Yusuke Matoba, Kyle M Devins, Lara Milane, William B Manning, Varvara Mazina, Oladapo O Yeku, Bo R Rueda
Although many recent advancements have been made in women's health, perhaps one of the most neglected areas of research is the diagnosis and treatment of high-grade endometrial cancer (EnCa). The molecular classification of EnCa in concert with histology was a major step forward. The integration of profiling for mismatch repair deficiency and Human Epidermal Growth Factor 2 (HER2) overexpression, can further inform treatment options, especially for drug resistant recurrent disease. Recent early phase trials suggest that regardless of subtype, combination therapy with agents that have distinct mechanisms of action is a fruitful approach to the treatment of high-grade EnCa...
April 24, 2024: Reproductive Sciences
#30
JOURNAL ARTICLE
Makiko Go, Michio Kimura, Shiori Yamada, Eiseki Usami, Yoshihiro Noguchi, Tomoaki Yoshimura
Background : Appropriate adverse event (AE) management and maintenance of therapeutic intensity are necessary to achieve therapeutic benefits of CDK4/6 inhibitors (palbociclib and abemaciclib) in hormone receptor-positive, HER2-negative metastatic/recurrent breast cancer. Objective : This study was aimed at clarifying the effect of AEs associated with palbociclib and abemaciclib on treatment. Methods : A total of 62 and 49 patients were prescribed palbociclib and abemaciclib, respectively, at our hospital from January 1, 2018 to June 30, 2023...
April 23, 2024: Journal of Pharmacy Practice
#31
JOURNAL ARTICLE
Saskia Leonard, Alyssa N Jones, Lisa Newman, Mariana Chavez-MacGregor, Rachel A Freedman, Erica L Mayer, Elizabeth A Mittendorf, Tari A King, Olga Kantor
PURPOSE: Breast cancer mortality is higher in Black women than other racial groups. This difference has been partially attributed to a higher proportion of triple-negative breast cancer (TNBC). However, it is uncertain if survival disparities exist in racially diverse TNBC patients receiving similar treatments. Here, we examine racial differences in disease-related outcomes in TNBC patients treated on the E5103 clinical trial. METHODS: From 2007 to 2011, 4,994 patients with stage I-III HER2-negative breast cancer were randomized to adjuvant chemotherapy with or without bevacizumab...
April 23, 2024: Breast Cancer Research and Treatment
#32
JOURNAL ARTICLE
Silvia Fenix-Caballero, Adrián Sanchez-Vegas, Emilio Jesús Alegre Del-Rey, David Epstein, Leticia Garcia-Mochon, Antonio Olry de Labry Lima
INTRODUCTION: Abemaciclib is an oral inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). Data from the clinical trial monarchE (2023) showed improved survival from invasive disease. The aim of the present article was to conduct an economic assessment of adjuvant treatment with abemaciclib in women with luminal, HER2- and node-positive breast cancer. METHODS: A Markov model was constructed with four mutually exclusive health states (disease-free, local recurrence, distal recurrence and death)...
April 22, 2024: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
#33
JOURNAL ARTICLE
Yan Liang, Jing Liu, Jia Ge, Qiyun Shi, Guozhi Zhang, Andi Wan, Tao Luo, Hao Tian, Linjun Fan, Shushu Wang, Li Chen, Peng Tang, Kai Zhu, Jun Jiang, Xiuwu Bian, Yi Zhang, Xiaowei Qi
BACKGROUND: Anlotinib is a new type of tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors 1/2/3, platelet-derived growth factor receptors α/β, and fibroblast growth factor receptors 1-4 and c-Kit, with a broad spectrum of inhibitory effects on tumor angiogenesis and growth. It has been proven effective in HER2-negative metastatic breast cancer, but its efficacy in early-stage triple-negative breast cancer (TNBC) is unknown. This phase 2 study aims to evaluate the efficacy and safety of adding anlotinib to neoadjuvant chemotherapy in patients with TNBC...
May 2024: EClinicalMedicine
#34
JOURNAL ARTICLE
Toshiaki Iwase, Evan N Cohen, Hui Gao, Angela Alexander, Megumi Kai, Vivian Chiv, Xiaoping Wang, Savitri Krishnamurthy, Diane Liu, Yu Shen, Kumiko Kida, Alexandre Reuben, Rachel Layman, David Ramirez, Debu Tripathy, Stacy L Moulder, Clinton Yam, Vicente Valero, Bora Lim, James M Reuben, Naoto T Ueno
PURPOSE: Accumulating toxicities hinder indefinite chemotherapy for many patients with metastatic/recurrent HER2-negative breast cancer. We conducted a phase II trial of pembrolizumab monotherapy following induction chemotherapy to determine the efficacy of maintenance immunotherapy in patients with metastatic HER2-negative inflammatory breast cancer (IBC) and non-IBC triple-negative breast cancer (TNBC) and a biomarker study. PATIENTS AND METHODS: Patients with a complete response (CR), partial response (PR), or stable disease (SD) after at least 3 cycles of chemotherapy for HER2-negative breast cancer received pembrolizumab, regardless of programmed death-ligand 1 expression...
April 17, 2024: Clinical Cancer Research
#35
JOURNAL ARTICLE
Eriko Narusawa, Sasagu Kurozumi, Ayaka Katayama, Yukio Koibuchi, Akira Ogawa, Daisuke Takata, Shoko Tokuda, Sayaka Obayashi, Tetsunari Oyama, Jun Horiguchi, Ken Shirabe, Takaaki Fujii
In some cases of human epidermal growth factor 2 (HER2)-negative breast cancer, including triple-negative breast cancer, HER2 expression is sporadically and strongly upregulated, a condition known as HER2 heterogeneity. We investigated the clinicopathological features of patients with HER2 heterogeneity in triple-negative breast cancers treated with neoadjuvant chemotherapy. Thirty-nine patients with triple-negative breast cancer who had undergone preoperative chemotherapy participated in this study. To assess for HER2 heterogeneity, we used dual in situ hybridization slides...
April 15, 2024: Medical Molecular Morphology
#36
Nabamita Boruah, David Hoyos, Renyta Moses, Ryan Hausler, Heena Desai, Anh N Le, Madeline Good, Gregory Kelly, Ashvathi Raghavakaimal, Maliha Tayeb, Mohana Narasimhamurthy, Abigail Doucette, Peter Gabriel, Michael J Feldman, Jinae Park, Miguel Lopez de Rodas, Kurt A Schalper, Shari B Goldfarb, Anupma Nayak, Arnold J Levine, Benjamin D Greenbaum, Kara N Maxwell
Pathogenic germline TP53 alterations cause Li-Fraumeni Syndrome (LFS), and breast cancer is the most common cancer in LFS females. We performed first of its kind multimodal analysis of LFS breast cancer (LFS-BC) compared to sporadic premenopausal BC. Nearly all LFS-BC underwent biallelic loss of TP53 with no recurrent oncogenic variants except ERBB2 (HER2) amplification. Compared to sporadic BC, in situ and invasive LFS-BC exhibited a high burden of short amplified aneuploid segments (SAAS). Pro-apoptotic p53 target genes BAX and TP53I3 failed to be up-regulated in LFS-BC as was seen in sporadic BC compared to normal breast tissue...
April 5, 2024: bioRxiv
#37
So-Young Lee, Hoon Seok Kim, Mi-Hyang Jung, Suyon Chang, Myungshin Kim, Jong-Chan Youn, Woo-Baek Chung, Hae Ok Jung
The prevention and management of cancer therapy-related cardiac dysfunction (CTRCD) have become increasingly important. Recent studies have revealed the crucial role of genetics in determining the susceptibility to development of CTRCD. We present a case of a 65-year-old woman with breast cancer who developed recurrent CTRCD following low-dose chemotherapy, despite lacking conventional cardiovascular risk factors. Her medical history included anthracycline-associated cardiomyopathy, and her condition deteriorated significantly after treatment with HER2-targeted therapies...
April 14, 2024: ESC Heart Failure
#38
JOURNAL ARTICLE
Elena Guerini-Rocco, Federica Bellerba, Alberto Concardi, Sergio Vincenzo Taormina, Giulio Cammarata, Caterina Fumagalli, Aliana Guerrieri-Gonzaga, Debora Macis, Eliza Del Fiol Manna, Emanuela Balladore, Maria Cannone, Paolo Veronesi, Nicola Fusco, Bernardo Bonanni, Giuseppe Viale, Massimo Barberis, Sara Gandini, Matteo Lazzeroni
BACKGROUND AND AIM: Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer with highly variable clinical behavior, but risk stratification is still challenging. We sought to identify immune-related gene expression signatures of pure DCIS associated with different risks of breast cancer recurrence. METHODS: A retrospective nested case-control study of 143 pure DCIS was performed including 70 women with subsequent ipsilateral breast event (IBE, in situ or invasive; cases) and 73 DCIS women with no IBE and matched for age, tumor size, treatment, hormone receptors/HER2 status, and follow-up time (controls)...
April 12, 2024: European Journal of Cancer
#39
REVIEW
Naoki Miyazaki, Toshiki Iwasaki, Hitomi Sakai, Rurina Watanuki, Yoshinori Tanizawa, Zhihong Cai, Tsutomu Kawaguchi, Junji Tsurutani, Kengo Nagashima
BACKGROUND: The clinicopathological factors indicating risk of recurrence are used to guide the choice of perioperative therapy in patients with breast cancer. Although several risk factors for recurrence have been reported in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) early breast cancer in Japan, there has been no systematic review quantifying potential risk factors. METHODS: We performed a systematic literature review and meta-analysis using the MEDLINE, Embase, Cochrane CENTRAL, and Japan Medical Abstract Society databases to identify risk factors for recurrence in HR+/HER2- early breast cancer in Japan...
April 10, 2024: Current Medical Research and Opinion
#40
JOURNAL ARTICLE
Akira Watanabe, Ryo Tsunashima, Chikage Kato, Sae Kitano, Saya Matsumoto, Yoshiaki Sota, Midori Morita, Koichi Sakaguchi, Yasuto Naoi
BACKGROUND: EndoPredict® (EP) is a multigene assay to predict distant recurrence risk in luminal breast cancer. EP measures the expression of 12 genes in primary tumor by qRT-PCR from formalin-fixed paraffin-embedded (FFPE) tissues and calculates EP risk score that indicates the risk of distant recurrence. We evaluated the performance of EP in predicting distant recurrence risk using microarray data from fresh frozen (FF) tissues. We also examined the applicability of EP to microarray data from FFPE tissues...
April 8, 2024: Breast Cancer: the Journal of the Japanese Breast Cancer Society
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
